Novacyt revenues full year 2017 PR ENG Delivers record revenue growth of 35% China sales exceed expectations Successfully completed dual-listing on AIM
Visit PageAuthor: novacyt
FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS
Novacyt Fast 500 PR Paris, France and Cambridge, UK – 2 January 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte’s Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in
Visit PageLiquidity Agreement Monthly Update and Total Voting Rights
Liquidity Agreement -1 December Paris, France and Cambridge, UK – 1 December 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by
Visit Page